CSL Ltd (AU:CSL) — Market Cap & Net Worth

$47.22 Billion USD  · AU$66.73 Billion AUD  · Rank #494

Market Cap & Net Worth: CSL Ltd (CSL)

CSL Ltd (AU:CSL) has a market capitalization of $47.22 Billion (AU$66.73 Billion) as of April 18, 2026. Listed on the AU stock exchange, this Australia-based company holds position #494 globally and #6 in its home market, demonstrating a -3.26% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying CSL Ltd's stock price AU$137.55 by its total outstanding shares 485151394 (485.15 Million).

CSL Ltd Market Cap History: 2015 to 2026

CSL Ltd's market capitalization history from 2015 to 2026. Data shows growth from $32.28 Billion to $47.22 Billion (5.40% CAGR).

Index Memberships

CSL Ltd is a constituent of 9 market indices:

Index Total Market Cap Weight (%) Rank by Market Cap
S&P/ASX 50
AFLI
$1.01 Trillion 4.68% #6 of 50
Australia All Ordinaries
AORD
$1.38 Trillion 3.43% #5 of 495
S&P/ASX 20
ATLI
$682.09 Billion 6.92% #5 of 20
S&P/ASX 100
ATOI
$1.24 Trillion 3.81% #6 of 100
S&P/ASX All Australian 50
AXAF
$912.44 Billion 5.17% #5 of 50
S&P/ASX All Australian 200
AXAT
$1.27 Trillion 3.72% #5 of 200
S&P/ASX 200
AXJO
$1.24 Trillion 3.80% #5 of 200
S&P/ASX 200 Accumulated
AXJOA
$1.24 Trillion 3.80% #5 of 200
S&P/ASX 300
AXKO
$1.46 Trillion 3.24% #6 of 300

Weight: CSL Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

CSL Ltd Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how CSL Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

3.84x

CSL Ltd's market cap is 3.84 times its annual revenue

Industry average: 3727.92x Lower than industry average

Latest Price to Earnings (P/E) Ratio

19.74x

CSL Ltd's market cap is 19.74 times its annual earnings

Industry average: 0.14x Higher than industry average

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2016 $31.31 Billion $6.06 Billion $1.24 Billion 5.17x 25.20x
2017 $44.66 Billion $7.02 Billion $1.34 Billion 6.36x 33.39x
2018 $59.24 Billion $7.46 Billion $1.27 Billion 7.94x 46.55x
2019 $89.30 Billion $8.32 Billion $1.92 Billion 10.74x 46.54x
2020 $92.63 Billion $9.41 Billion $2.17 Billion 9.85x 42.63x
2021 $96.07 Billion $10.33 Billion $2.39 Billion 9.30x 40.19x
2022 $96.20 Billion $10.49 Billion $2.25 Billion 9.17x 42.67x
2023 $97.07 Billion $13.17 Billion $2.19 Billion 7.37x 44.24x
2024 $96.66 Billion $14.69 Billion $2.64 Billion 6.58x 36.59x
2025 $59.27 Billion $15.43 Billion $3.00 Billion 3.84x 19.74x

Competitor Companies of CSL by Market Capitalization

Companies near CSL Ltd in the global market cap rankings as of April 18, 2026.

Key companies related to CSL Ltd by market ranking:

  • Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $110.53 Billion USD.
  • Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #292 globally with a market cap of $77.51 Billion USD.
  • CSL Limited (F:CSJ): Ranked #513 globally with a market cap of $45.38 Billion USD ( €38.82 Billion EUR).
  • Argen-X (F:1AE): Ranked #532 globally with a market cap of $44.01 Billion USD ( €37.64 Billion EUR).
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#183 Vertex Pharmaceuticals Inc NASDAQ:VRTX $110.53 Billion $435.65
#292 Regeneron Pharmaceuticals Inc NASDAQ:REGN $77.51 Billion $746.00
#513 CSL Limited F:CSJ $45.38 Billion €82.45
#532 Argen-X F:1AE $44.01 Billion €712.00

CSL Ltd Historical Marketcap From 2015 to 2026

Between 2015 and today, CSL Ltd's market cap moved from $32.28 Billion to $ 47.22 Billion, with a yearly change of 5.40%.

Year Market Cap Change (%)
2026 AU$47.22 Billion -20.33%
2025 AU$59.27 Billion -38.69%
2024 AU$96.66 Billion -0.42%
2023 AU$97.07 Billion +0.91%
2022 AU$96.20 Billion +0.13%
2021 AU$96.07 Billion +3.72%
2020 AU$92.63 Billion +3.72%
2019 AU$89.30 Billion +50.75%
2018 AU$59.24 Billion +32.64%
2017 AU$44.66 Billion +42.66%
2016 AU$31.31 Billion -3.02%
2015 AU$32.28 Billion --

End of Day Market Cap According to Different Sources

On Apr 17th, 2026 the market cap of CSL Ltd was reported to be:

Source Market Cap
Yahoo Finance $47.22 Billion USD
MoneyControl $47.22 Billion USD
MarketWatch $47.22 Billion USD
marketcap.company $47.22 Billion USD
Reuters $47.22 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About CSL Ltd

AU:CSL Australia Biotechnology
Market Cap
$47.22 Billion
AU$66.73 Billion AUD
Market Cap Rank
#494 Global
#6 in Australia
Share Price
AU$137.55
Change (1 day)
-1.36%
52-Week Range
AU$134.62 - AU$272.00
All Time High
AU$321.70
About

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma produ… Read more